Lineage Q1 2022 Earnings Report
Key Takeaways
Lineage Cell Therapeutics reported first quarter 2022 financial results, including revenues of $5.2 million, primarily from licensing fees related to the Roche collaboration, and a net loss of $7.1 million, or $0.04 per share.
Launched new cell therapy programs in hearing loss and vision disorders.
Conducted tech transfer activities to support alliance with Roche and Genentech for dry AMD program.
Expanded cell therapy pipeline to five distinct programs.
Focus is on clinical and regulatory execution across the portfolio, advancing OPC1 and VAC2 into next phases of clinical testing.
Lineage
Lineage
Forward Guidance
Lineage anticipates reaching significant events with each of their clinical and preclinical programs, supported by a disciplined use of capital and current balance sheet.